By encoding an output gene for GLP-1 (glucagon-like peptide-1) under an NFAT (nuclear factor of activated T cells)-dependent inducible promoter and implanting the engineered cells into a mouse model of diabetes, they obtained a closed-loop system to correct hyperglycemia in vivo. The gene discussed is GCG; the disease is diabetes mellitus.